We previously reported that the risk of BCP ALL was greater in DPB1*0201 heterozygotes than homozygotes (Taylor et al, 2002), suggesting that BCP ALL might be the rare ‘down-side’ of the advantage that MHC-heterozygosity confers on immune responses to infection. The gene discussed is HLA-DPB1; the disease is acute lymphoblastic leukemia.